ClinicalTrials.gg

Program

tasimelteon

Also written as “Tasimelteon”, “Tasimelteon Oral Suspension” and “Tasimelteon Oral Capsule”.

Its studies are mostly in Sleep Disorders, Circadian Rhythm · Sleep Initiation and Maintenance Disorders · Depressive Disorder, Major · Renal Insufficiency · Liver Diseases, led by Vanda Pharmaceuticals.

Furthest: phase 4, since May 1, 201425 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals253 open or runningphase 4since May 1, 2014Feb 3, 2006Nov 2027phase 3 · NCT06953869

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Feb 3, 2006.

  1. Jan 26, 2012Phase 1 study in Renal InsufficiencyNCT01526746 · 32 enrolled · United States
  2. Feb 22, 2012Phase 1 study in Healthy VolunteersNCT01540500 · 24 enrolled · United States
  3. Apr 12, 2012Phase 1 study in Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With EthanolNCT01578057 · 28 enrolled · Canada
  4. Jun 28, 2012Phase 1 study in HealthyNCT01637636 · 48 enrolled · United States
  5. May 1, 2014Phase 4 study in Sleep Disorders, Circadian RhythmNCT02130999 · 14 enrolled
  6. Aug 29, 2014Phase 3 study in Smith-Magenis SyndromeNCT02231008 · 49 enrolled · United States
  7. May 16, 2016Phase 1 study in Sleep Disorders, Circadian RhythmNCT02776215 · 24 enrolled · United States
  8. Sep 8, 2016Phase 2 study in Jet Lag DisorderNCT03291041 · 25 enrolled · United States
  9. Oct 31, 2017Phase 3 study in Jet Lag Type InsomniaNCT03373201 · 320 enrolled · United States
  10. Oct 18, 2019Phase 1 study in Healthy VolunteersNCT06323655 · 48 enrolled · Canada
  11. Nov 19, 2020Phase 3 study in Sleep Wake DisordersNCT04652882 · 43 enrolled · United States, Austria, Germany
  12. Jul 5, 2022Phase 1 study in HealthyNCT05572281 · 36 enrolled · United States
  13. Nov 14, 2024Phase 3 study in Sleep Wake DisordersNCT06701396 · 60 planned · Turkey
  14. Apr 1, 2025Phase 3 study in Sleep Initiation and Maintenance DisordersNCT06953869 · 420 planned · United States, Germany, Poland and more

Ahead

  1. Nov 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT06953869

TargetBeta

“Melatonin receptor agonist”ChEMBL 37, by rule

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06953869Sleep Initiation and Maintenance Disorders · United States, Germany, Poland and more3RecruitingNov 2027420
NCT06701396Sleep Wake Disorders · Turkey3RecruitingJun 30, 202560
NCT05572281Healthy · United States1CompletedJun 15, 202236
NCT04652882Sleep Wake Disorders · United States, Austria, Germany3CompletedSep 4, 202643
NCT06323655Healthy Volunteers · Canada1CompletedAug 28, 201848
NCT03373201Jet Lag Type Insomnia · United States3CompletedMar 5, 2018320
NCT03291041Jet Lag Disorder · United States2CompletedNov 201725
NCT02776215Sleep Disorders, Circadian Rhythm · United States1CompletedDec 20, 201724
NCT02231008Smith-Magenis Syndrome · United States3CompletedNov 19, 201849
NCT02130999Sleep Disorders, Circadian Rhythm4CompletedMay 201414
NCT01637636Healthy · United States1CompletedAug 201248
NCT01578057Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol · Canada1CompletedJun 201228
NCT01540500Healthy Volunteers · United States1CompletedMar 201224
NCT01526746Renal Insufficiency · United States1CompletedJun 201232
NCT01477619Healthy Volunteers · United States1CompletedJan 201260
NCT01428661Depressive Disorder, Major · United States3CompletedJan 2013507
NCT01430754Sleep Disorders, Circadian Rhythm · United States3CompletedDec 201220
NCT01429116Sleep Disorders, Circadian Rhythm · United States3CompletedJan 2015200
NCT01402076Healthy Volunteers · United States1CompletedAug 201124
NCT01271387Liver Diseases · United States1CompletedAug 201129
NCT01218789Sleep Disorders, Circadian Rhythm · France3Active, not recruitingDec 5, 2024140
NCT01163032Sleep Disorders, Circadian Rhythm · United States, Germany3CompletedNov 2012136
NCT00548340Sleep Initiation and Maintenance Disorders · United States3CompletedFeb 2008322
NCT00490945Sleep Disorders, Circadian Rhythm · United States2CompletedMar 200545
NCT00291187Sleep Initiation and Maintenance Disorders · United States3CompletedAug 2006411

How it is read

Names in the registry

  • “tasimelteon”, 11 entries
  • “Tasimelteon”, 10 entries
  • “Tasimelteon Oral Suspension”, 2 entries
  • “Tasimelteon Oral Capsule”, 1 entry
  • “tasimelteon 20 mg capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.